Antianemic effect of once weekly regimen of epoetin alfa 40,000 units in anemic cancer patients receiving chemotherapy

Journal of the Medical Association of Thailand

Volumn 90, Issue 6, 2007, Pages 1082-1088

  Voravud, Narin ^a   Sriuranpong, Virote ^a   Suwanrusme, Harit ^a  

^a CHULALONGKORN UNIVERSITY   (Thailand)

Author keywords

Anemia; Epoetin alfa; Non myeloid malignancy; Quality of life

Indexed keywords

ANTINEOPLASTIC AGENT; HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ANEMIA; ARTICLE; CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL ARTICLE; COUGHING; DAILY LIFE ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; MALE; OPEN STUDY; QUALITY OF LIFE;

ADULT; AGED; ANEMIA; ANTINEOPLASTIC AGENTS; EPOETIN ALFA; FEMALE; HEMATINICS; HEMOGLOBINS; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; QUALITY OF LIFE; QUESTIONNAIRES; TREATMENT OUTCOME;

EID: 34347323825     PISSN: 01252208     EISSN: 01252208     Source Type: Journal    
DOI: None     Document Type: Article

References (7)

1. The National Comprehensive Cancer Network (NCCN). Practice Guidelines in Oncology. Cancer and treatment-related anemia. Version 2. NCCN; 2006.
2. Albels RI, Larholt KM, Krantz KD, Bryant EC. Recombinant human erythropointin (r-HuEPO) for the treatment of the anemia of cancer. In: Murphy MJ Jr, editor. Blood cell growth factors: their present and future use in haematology and oncology. Proceedings of the Beijing Symposium. Dayton, Ohio: AlphaMedical Press; 1991: 121-41.
3. Package insert PROCRIT. Raritan, New Jersey: Ortho Biotech; 2/97.
4. Voravud N, Sriuranpong V. Clinical benefits of epoetin alfa (Eprex) 10,000 units subcutaneously thrice weekly in Thai cancer patients with anemia receiving chemotherapy. J Med Assoc Thai 2005; 88: 607-12.
5. Goldberg MA, McCutchen JW, Jove M, Di Cesare P, Friedman RJ, Poss R, et al. A safety and efficacy comparison study of two dosing regimens of epoetin alfa in patients undergoing major orthopedic surgery. Am J Orthop 1996; 25: 544-52.
6. Witzig TE, Silberstein PT, Loprinzi CL, Sloan JA, Novotny PJ, Mailliard JA, et al. Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy. J Clin Oncol 2005; 23: 2606-17.
7. Cheung WC, Wacholtz MC, Young DC. Pharmacokinetics (PK) and pharmacodynamics (PD) of weekly and T. I. W. subcutaneous doses of recombinant human erythropoietin in healthy subjects [Abstract # 3547]. Blood 1997; 90(Suppl Pt 2): 183b.